NCT05462873 - A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

January 20, 2026

Study Completion Date

January 20, 2026

Conditions

Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellEsophageal Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL

QEQ278

Intravenous dosing of QEQ278

Trial Locations (12)

Novartis Investigative Site, Brussels

Novartis Investigative Site, Taipei

Novartis Investigative Site, Milan

Florida Cancer Specialists, Fort Myers

Novartis Investigative Site, Essen

Novartis Investigative Site, Paris

University of California LA, Los Angeles

Novartis Investigative Site, Singapore

Massachusetts General Hospital Dept. of Mass General Hospital, Boston

Massachusetts General Hospital, Boston

Novartis Investigative Site, Kashiwa

Novartis Investigative Site, Barcelona